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SCIENTIFIC LETTER
Early detection of left ventricular dysfunction in patients
with β thalassaemia major by dobutamine stress
echocardiography
L Hui, M P Leung, S Y Ha, A K T Chau, Y F Cheung
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Myocardial iron deposition, among other factors, con-tributes to left ventricular (LV) dysfunction in patientswith β thalassaemia major.1 Nonetheless, conven-
tional indices have not been particularly useful for its early
detection. Importantly, cardiac function deteriorates rapidly
once clinical symptoms develop. Dobutamine stress echo-
cardiography (DSE) is well accepted in the evaluation of myo-
cardial dysfunction caused by coronary artery disease in
adults.2 In children, DSE has been used for early detection of
LV dysfunction in long term childhood cancer survivors.3 In
this study, we assessed the usefulness of DSE for early detec-
tion of LV dysfunction in thalassaemia patients.
METHODS
Twenty six patients (17 females) with β thalassaemia major
with a mean (SD) age of 17.4 (8.3) years (range 4–33 years)
were studied. Their body surface area (BSA) was 1.12
(0.20) m2. None had congestive heart failure clinically and all
were in New York Heart Association (NYHA) functional class I
at initial assessment. Monthly blood transfusion was started
at a median of 11 months (range 3–96 months), while desfer-
rioxamine was started at a median age of 30 months (range
25–114 months). Post-transfusion haemoglobin was targeted
at 14 g/dl (8.7 mmol/l), and echocardiographic studies were
performed within one week of transfusion to minimise
confounding influence of anaemia. Only one of the patients
had undergone splenectomy. Twenty healthy subjects (13
females) aged 10.4 (4.5) years (range 4–15 years), with a BSA
of 1.40 (0.23) m2, were recruited as controls. The institutional
ethics committee approved the study and parents or subjects
themselves gave informed consent.
Transthoracic echocardiography was performed using
Vingmed System 5 (Horton, Norway) ultrasound machine.
Echocardiographic assessments were performed after 15 min-
utes of rest and after 10 minutes of dobutamine infusion
(5 µg/kg/min). Cineloop data were digitised for offline
analysis. Blood pressure was measured using an oscillometric
device (Critikon, Dinamap, Tampa, Florida, USA). After the
first DSE assessment, a repeated non-stressed echocardio-
graphic assessment was performed in patients at an interval
of two years.
Standard parasternal short axis view was used to derive the
following4: LV end systolic dimension (LVESD), LV end-
diastolic dimension (LVEDD) and LV posterior wall thickness
at systole (LVPWS). The fractional shortening (FS) and
ejection fraction (EF) of the left ventricle were calculated
according to standard formulae: FS = [LVEDD − LVESD]/
LVEDD; EF = [LVEDD3 − LVESD3]/LVEDD3. The aortic ejection
time (ET) and RR interval were measured by pulsed Doppler
and from surface ECG, respectively. Rate corrected velocity of
circumferential fibre shortening (Vcfc) was calculated by Vcfc
= RR × FS/ET, while LV systolic meridional wall stress (WS)
was calculated byWS= [0.337 × LVESP × LVESD]/LVPWS [1+
LVPWS/LVESD]. The peak systolic pressure was used to
estimate LV end systolic pressure (LVESP) as this avoided the
need for carotid tracing which is technically demanding in
children. Average values of indices obtained from three
consecutive cardiac cycles were used for analysis. The
reference LV myocardial contractility index, a relatively load
independent index based on the relation between Vcfc and
WS,was derived from controls using linear regression at base-
line and under dobutamine stress. Patients with data points
lying below the 95% confidence limit were regarded as having
impaired myocardial contractility.5
Data are expressed as mean (SD). Differences in indices
between patients and controls were compared using unpaired
Student’s t test, while differences between first and second
assessments in patients were compared using paired Student’s
t test. A probability value of p < .05 was considered
significant.
RESULTS
There were no significant differences in echocardiographic
indices between patients and controls in the first assessment
at rest (table 1). Three of the 26 patients, however, had a
reduced contractility index. During dobutamine stress, pa-
tients had a significantly lower FS, EF, and Vcfc, and a higher
WS (table 1). Furthermore, 11 of the 26 patients were found to
have a subnormal myocardial contractility index.
Twenty four of the 26 patients underwent a second assess-
ment. One patient, who had impaired LV contractility under
dobutamine stress, died of congestive heart failure, while the
other declined reassessment. Of the remaining 24 patients, 14
(normal subset) had a normal LV contractility index under
dobutamine stress two years earlier, while 10 (abnormal sub-
set) had subnormal LV contractility. For the normal subset,
there were no significant differences in echocardiographic
indices between the first and second assessments (table 1). All
of these patients remained in NYHA functional class I.
However, for the abnormal subset, there was a significant
reduction in FS, EF, and Vcfc on follow up assessment (table
1). All had a subnormal myocardial contractility index at fol-
low up even in the absence of stress. Furthermore, eight of the
10 patients in the abnormal subset had worsening of the
NYHA functional class on follow up, seven in class II and one
in class III. Thus a subnormal myocardial contractility index
under dobutamine stress has a sensitivity of 80% and a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: DSE, dobutamine stress echocardiography; EF, ejection
fraction; ET, ejection time; FS, fractional shortening; LV, left ventricular;
LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular
end systolic dimension; LVESP, left ventricular end systolic pressure;
LVPWS, left ventricular posterior wall thickness at systole; NYHA, New
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specificity of 100% of predicting worsening of functional class
at a follow up interval of two years.
DISCUSSION
This study demonstrates that DSE may be useful for early
detection of LV dysfunction in thalassaemia patients. Those
with impaired myocardial contractility on DSE had a
significantly worse functional class and resting LV function at
reassessment two years after the first examination. Nonethe-
less, confounding influence of pulmonary dysfunction, sec-
ondary to iron deposition, on functional class assessment can-
not be completely excluded. While myocardial iron deposition
undoubtedly contributes to LV dysfunction, multiple factors
including superimposed myocarditis and immunogenetic pro-
file do interact to result in eventual LV failure.1
The optimal dobutamine dose for assessment of LV reserve
in children remains controversial. Nonetheless, frequent side
effects has been reported to occur with an infusion rate of
> 10 µg/kg/min.3 As we were assessing myocardial contractile
reserve rather than coronary arterial flow limiting lesions, a
low dose dobutamine infusion regimen3 was used.
Certain limitations deserve comment. Firstly, the age of the
controls was not entirely matched to those of the patients.
Nonetheless, previous studies have shown that the stress–
velocity relation is relatively age independent.5 Secondly, the
relatively small number of controls might have widened the
confidence intervals, which, however, would result in under
diagnosis rather than over diagnosis of patients with impaired
myocardial contractility. Thirdly, aortic ET was not assessed
simultaneously with M mode echocardiography, but nonethe-
less usually within a 30 second interval.
In conclusion, findings of this study suggest that DSE may
be useful for early detection of LV dysfunction in patients with
β thalassaemia major.
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Table 1 Comparison of echocardiographic indices between patients and controls at rest and under dobutamine stress
(left hand columns), and comparison of indices between first and second echocardiographic assessment in “normal” and
“abnormal” subsets (right hand columns)
Variables
Initial assessment First versus second assessments





















RR (s) 0.80 (0.15) 0.79 (0.16) 0.78 (0.13)** 0.70 (0.13) 0.82 (0.16) 0.82 (0.14) 0.77 (0.15) 0.71 (0.14)
ET (s) 0.30 (0.03) 0.30 (0.03) 0.29 (0.05)** 0.26 (0.04) 0.30 (0.02) 0.29 (0.04) 0.31 (0.03) 0.33 (0.03)
FS (%) 0.38 (0.05) 0.41 (0.05) 0.47 (0.07)*** 0.54 (0.04) 0.38 (0.05) 0.35 (0.05) 0.35 (0.02) 0.32 (0.04)*
EF (%) 0.76 (0.06) 0.80 (0.06) 0.84 (0.08)*** 0.90 (0.03) 0.76 (0.07) 0.71 (0.07) 0.76 (0.05) 0.68 (0.06)***
Vcfc (circ/s) 1.11 (0.16) 1.23 (0.21) 1.42 (0.24)*** 1.73 (0.26) 1.13 (0.16) 1.09 (0.15) 1.08 (0.17) 0.82 (0.11)***
WS (g/cm2) 64.34 (14.23) 72.67 (11.65) 59.89 (22.80)** 46.18 (15.57) 65.03 (16.38) 72.89 (14.68) 63.11 (11.90) 60.10 (9.62)
Ferritin (µmol/l) – – – – 4253 (792) 4935 (831) 5647 (769) 6741 (1347)*
Values are mean (SD).
*p<0.05; **p<0.01; ***p<0.001.
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